Researchers at Harvard, Peking University, and Yikon Genomics suggested that their noninvasive test is more specific than the prevailing biopsy-based method.
MSK-ACCESS sequences 129 cancer-associated genes selected from the MSK-IMPACT assay and is designed to detect gene alterations in cfDNA specimen.
Resolution is developing its liquid biopsy assay as a companion diagnostic for niraparib in metastatic castration-resistant prostate cancer.
SensID specializes in the development, manufacture, and marketing or reference materials and quality controls for DNA-based diagnostics.
The company's first quarter revenues were driven by sales of its noninvasive prenatal screening and carrier screening tests.
The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
Take2 Health plans to launch an nasopharyngeal carcinoma early detection test in the next several months in Hong Kong and southern China.
Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.
The company filed its first suit against Natera in March, claiming the firm's kidney transplant test infringes patents underlying CareDx's AlloSure test.
The Medicare contractor said in its draft guidance it would provide limited coverage for the cell-free DNA assay, which should be used as a supplemental test.